Back

HELIOS-B: Vutrisiran reduces all-cause mortality

17 May 2025 (11:50 - 11:58)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (1) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

20 More presentations in this session

Presentation thumbnail
FINEARTS­HF: Blinded drug withdrawal
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Discussant review - FINEARTS-HF
Doctor M. Costanzo (Naperville, US)
Slides Video
Presentation thumbnail
Panel discussion - FINEARTS-HF
Video
Presentation thumbnail
FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrin saturation
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Discussant review - FAIR-HF2 DZHK05
Doctor V. Chopra (New Delhi, IN)
Slides Video

Access the full session

Session thumbnail
Hottest trials and trial updates (1)
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 11:50 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
30 August 2024
thumbnail
Congress Presentation
What is coming now?
31 August 2025
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
30 August 2025
thumbnail
Congress Presentation
Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources